{
    "clinical_study": {
        "@rank": "77228", 
        "arm_group": {
            "arm_group_label": "LEE011", 
            "arm_group_type": "Experimental", 
            "description": "LEE011"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate safety and tolerability to estimate the MTD and/or recommended dose\n      for expansion."
        }, 
        "brief_title": "A Phase I Study of LEE011 in Asian Patients", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "detailed_description": {
            "textblock": "This is a multi-center, open label, dose finding, phase I study of oral single agent LEE011,\n      administered once daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with a histologically confirmed diagnosis of a solid tumor\n\n          -  ECOG PS <2\n\n          -  Good organ function at screening visit\n\n          -  A sufficient interval mast have elapsed between the last dose of prior anti-cancer\n             therapy\n\n        Exclusion Criteria:\n\n          -  Impairment of GI function\n\n          -  Patients with concurrent severe and/or uncontrolled concurrent medical conditions\n\n          -  Known diagnosis of HIV or active viral hepatitis\n\n          -  Pregnant or nursing (lactating) women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898845", 
            "org_study_id": "CLEE011X1101"
        }, 
        "intervention": {
            "arm_group_label": "LEE011", 
            "intervention_name": "LEE011", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Neoplasms", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency (PMDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of dose limiting toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "First cycle (28 days)"
            }, 
            {
                "measure": "Maximum tolerated dose (MTD) and/or recomended dose (RD)", 
                "safety_issue": "Yes", 
                "time_frame": "First cycle (28 days)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessed by incidence, duration and severity of adverse events and serious adverse events; changes in clinical laboratory values, vital signs and ECGs; tolerability of study drug (dose interruption, dose reduction)", 
                "measure": "Safety and Tolerability of LEE011", 
                "safety_issue": "Yes", 
                "time_frame": "from informed consent till 28 days after end of treatment"
            }, 
            {
                "description": "Concentration of LEE011 and PK parameters (e.g. Cmax and AUC)", 
                "measure": "PK parameters of LEE011", 
                "safety_issue": "No", 
                "time_frame": "every week up to first 4 weeks, once a week in the subsequent 2 weeks"
            }, 
            {
                "description": "To assess preliminaly anti-tumor activity based on RECIST", 
                "measure": "Best overall response", 
                "safety_issue": "No", 
                "time_frame": "every 2 months until 28 days after end of treatment"
            }, 
            {
                "description": "To assess preliminaly anti-tumor activity based on RECIST", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "every 2 months until 28 days after end of treatment"
            }, 
            {
                "description": "To assess preliminaly anti-tumor activity based on RECIST", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "every 2 months until 28 days after end of treatment"
            }, 
            {
                "description": "To assess preliminaly anti-tumor activity based on RECIST", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "every 2 months until 28 days after end of treatment"
            }, 
            {
                "description": "To assess preliminaly anti-tumor activity based on RECIST", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "every 2 months until 28 days after end of treatment"
            }, 
            {
                "description": "To assess preliminaly anti-tumor activity based on RECIST", 
                "measure": "Overall response", 
                "safety_issue": "No", 
                "time_frame": "every 2 months until 28 days after end of treatment"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}